Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-22T16:51:59.611Z Has data issue: false hasContentIssue false
  • English
  • Français

Editorial Review: Therapeutic Trials in Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

J.H. Noseworthy ,
T.P. Seland  and
G.C. Ebers
J.H. Noseworthy*
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London, Ontario and the Department of Clinical Neurosciences, University of Calgary, Calgary
T.P. Seland
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London, Ontario and the Department of Clinical Neurosciences, University of Calgary, Calgary
G.C. Ebers
Affiliation:
Department of Clinical Neurological Sciences, University Hospital, London, Ontario and the Department of Clinical Neurosciences, University of Calgary, Calgary
*
Department of Clinical Neurological Sciences, University Hospital, 339 Windermere Road, London, Ontario, Canada N6A 5A5
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Special Features
Information
Canadian Journal of Neurological Sciences , Volume 11 , Issue 3 , August 1984 , pp. 355 - 362
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Abreu, SL (1982) Suppression of experimental allergic encephalomyelitis by interferon. Immuno Commun. 11: 1–7.CrossRefGoogle ScholarPubMed
Aimard, G, Confavreux, C, Trouillas, P, et al. (1977) Our experience of azathioprine treatment in multiple sclerosis. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in Multiple Sclerosis, Ghent, Belgium, European Press, pp. 38–45.Google Scholar
Alvord, EG, Shaw, C, Hruby, S (1979) Myelin basic protein treatment of experimental allergic encephalomyelitis in monkeys. Ann. Neurol. 6: 469–473.CrossRefGoogle ScholarPubMed
Basten, A, Pollard, JD, Stewart, JD, Frith, JA, McLeod, JG, Walsh, JC, Garrick, R, Van Der Brink, CM (1980) Transfer factor in treatment of multiple sclerosis. Lancet (8201). 931–934.CrossRefGoogle ScholarPubMed
Bates, D, Fawcett, PRW, Shaw, DA, Weightman, D (1978) Polyunsaturated fatty acids in treatment of acute multiple sclerosis. B. Med. J. ii: 1390–1391.CrossRefGoogle Scholar
Behan, PO, Durward, WF, Melville, ID, McGeorge, AP, Behan, WMH (1976) Transfer factor therapy in multiple sclerosis. Lancet, i: 988–990.CrossRefGoogle Scholar
Binz, H, Wigzell, H (1975) Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. I. Demonstration of similar or identical idiotypes on IgG molecules and T-cell receptors with specificity for the same alloantigens. J. Exp. Med. 142: 197–211.CrossRefGoogle ScholarPubMed
Bolton, C, Borel, JF, Cuzner, ML, Davison, AN, Turner, AM (1982a) Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis. J. Neurol. Sci. 56: 147–153.CrossRefGoogle ScholarPubMed
Bolton, C, Allsopp, G, Cuzner, ML (1982b) The effect of cyclosporin A on the adaptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Clin. Exp. Immunol. 47: 127–132.Google Scholar
Borel, JF, Feurer, C, Gubler, HU, Stahelin, H (1976) Biological effects of cyclosporin A: A new anti-lymphocytic agent. Agents Actions 6: 468–475.CrossRefGoogle Scholar
Bornstein, MB, Miller, AI, Teitelbaum, D, Arnon, R, Sela, M (1982) Multiple sclerosis: Trial of a synthetic polypeptide. Ann. Neurol. 11:317–319.CrossRefGoogle ScholarPubMed
Britton, S, Palacius, R (1982) Cyclosporin A – usefulness, risks and mechanism of action. Immunological Rev. 65: 5–22.CrossRefGoogle ScholarPubMed
Brown, JR, Beebe, GW, Kurtzke, JF, Loewenson, RB, Silberberg, DH, Tourellotte, WW (1979) The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 29: 3–23.CrossRefGoogle ScholarPubMed
Campbell, B, Vogel, PJ, Fisher, E, Lorenz, R (1973) Myelin basic protein administration in multiple sclerosis. Arch. Neurol. 29: 10–15.CrossRefGoogle ScholarPubMed
Castaigne, P, Lhermitte, F, Escourolle, R, Hauw, JJ, Gray, F, Lyon-Caen, O (1981) Les Scleroses en plaques asymptomatiques. Rev. Neurol. (Paris). 137: 729–739.Google Scholar
Cendrowski, WS (1971) Therapeutic trial of imuran (azathioprine) in multiple sclerosis. Acta Neurol. Scandinav. 47: 254–260.CrossRefGoogle ScholarPubMed
Cendrowski, WS (1973) Combined therapeutic trial in multiple sclerosis. Hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside. Acta Neurol. Belgica 73: 209–219.Google ScholarPubMed
Cendrowski, W, Cztonkowska, A (1976) Penicillamine in multiple sclerosis. Acta Neurol. Scandinav. 54: 281–286.CrossRefGoogle ScholarPubMed
Cendrowski, W, Cztonkowska, A (1978) Levamisole in multiple sclerosis, with special reference to immunological parameters. A pilot study. Acta Neurol. Scandinav. 57: 354–359.CrossRefGoogle ScholarPubMed
Collins, RC, Espinoza, LR, Plank, CR, Ebers, GC, Rosenberg, RA, Zabriski, JB (1978) A double-blind trial of transfer factor vs. placebo in multiple sclerosis patients. Clin. Exp. Immunol., 33: 1–11.Google ScholarPubMed
Dau, PC, Johnson, KP, Spitler, LE (1976) The effect of levamisole on cellular immunity in multiple sclerosis. Clin. Exp. Immunol. 226: 302–309.Google Scholar
Dau, PC, Petajan, JH, Johnson, KP, Panitch, HS, Bornstein, MB (1980) Plasmapheresis in multiple sclerosis: Preliminary findings. Neurology 30: 1023–8.CrossRefGoogle ScholarPubMed
Doherty, P, Sampson, E (1982) Murine models of multiple sclerosis, Nature 299: 106–107.CrossRefGoogle ScholarPubMed
Ebers, GC (1982) A study of CSF idiotypes in MS. Scand. J. of Immunol. 16: 151–162.CrossRefGoogle Scholar
Ebers, GC, Vinuela, FV, Feasby, T, Bass, B (1984) Multifocal CT enhancement in MS. Neurology 34: 341–346.CrossRefGoogle ScholarPubMed
Editorial (1983) Cyclosporin and neoplasia. Lancet, i: 1083.Google Scholar
Fishbeck, KH (1983) Letter: N. Engl. J. Med. 309: 239–240.Google Scholar
Fisher, BH, Marks, M, Reich, T (1983) Hyperbaric-oxygen treatment in multiple sclerosis. A randomized placebo-controlled, double-blind study. N. Engl. J. Med. 308: 181–6.CrossRefGoogle Scholar
FogT (1965) The long-term treatment of multiple sclerosis with corticoids. Acta Neurol. Scand. 41. (Suppl. 13, Part 2): 473–484.Google Scholar
Fog, T, Raun, NS, Pederson, L, Kam-Hansen, S, Mellerup, E (1978) Long-term transfer-factor treatment for multiple sclerosis. Lancet i: 851–853.CrossRefGoogle Scholar
Frick, E, Angstwurm, H, Blomer, Ret al. (1977) Long-term treatment of multiple sclerosis with azathioprine. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in multiple sclerosis. Ghent, Belgium, European Press, pp. 88–98.Google ScholarPubMed
Georgi, W (1961) Multiple Sklerose. Pathologisch-anatomische befunde multipler skerose bei Klinisch nicht diagnostizierten Krankheiten. Schqiz Med Wsclv. 91: 605–607.Google Scholar
Gilbert, JJ.Sadler, M (1983) Unsuspected multiple sclerosis. Arch Neurol. 40: 533–536.Google Scholar
Gonsette, RE, Delmotte, P (1977) Intensive immunosuppression with cyclophosphamide in multiple sclerosis. J. Neurol. 214: 173–181.CrossRefGoogle ScholarPubMed
Gonsette, RE, Delmotte, P, Demonty, L (1977) Failure of basic protein therapy for multiple sclerosis. J. Neurol. 216: 27–31.CrossRefGoogle ScholarPubMed
Gonsette, RE, Demonty, L, Delmotte, P, de Cock, W, Verhaegen, H, Symoens, J (1982) Modulation of immunity in multiple sclerosis: A doubleblind levamisole-placebo controlled study in 85 patients. J. Neurol. 228: 65–72.CrossRefGoogle ScholarPubMed
Hauser, SL, Dawson, DM, Lehrich, JRet al. (1983) Intensive immunosuppression in progressive multiple sclerosis. N. Eng. J. Med. 308: 173–180.CrossRefGoogle ScholarPubMed
Herndon, RM, Murray, TJ (1983) Proceedings of the International Conference on therapeutic trials in multiple sclerosis. Arch. Neurol. 40: 663–710.Google Scholar
Hommes, OR, Lamers, KJB (1977) Immunosuppressive treatment in chronic progressive multiple sclerosis. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in multiple sclerosis. Ghent, Belgium. European Press, pp. 48–64.Google Scholar
Huston, DPet al. (1983) Letter. N. Eng. J. Med. 309: 241.Google Scholar
Jacobs, L, O’Malley, J, Freeman, A, Murawski, J (1982) Intrathecal interferon in multiple sclerosis. Arch. Neurol. 39: 609–615.CrossRefGoogle ScholarPubMed
Jerne, NK (1974) Towards a network theory of the immune system. Ann. Immunol. (Inst. Pasteur). 125C: 373–389.Google ScholarPubMed
Keith, AB, Arnon, R, Teitelbaum, D, Caspary, EA, Wisniewski, HM (1979) The effect of COP I, a synthetic polypeptide on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol. Sci. 42: 267–274.CrossRefGoogle Scholar
Khatri, BO, Harrington, GJ, Schmoll, D, McQuillen, MP (1983) A double-blind randomized controlled study of immunosuppressive drug therapy (IDT) with plasmapheresis (PP) in chronic progressive multiple sclerosis. Neurology. 33 (Suppl. 2): 178–179.Google Scholar
Kunkel, HG, Mannik, M, Williams, RC (1963) Individual antigenic specificity of isolated antibodies. Science 140: 1218–1219.CrossRefGoogle ScholarPubMed
Kurtzke, JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (DSS). Neurology. 33:1444–1452.CrossRefGoogle Scholar
Lamoureux, G, Cosgrove, J, Duquette, P, Lapierre, Y, Jolicoeur, R, Vanderland, F (1981) A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients. Clin. Exp. Immunol. 43: 577–584.Google ScholarPubMed
Lance, EM, Kriemer, M, Abbosh, J, Jones, VE, Knight, S, Medawar, PB (1975) Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response. Clin. Exp. Immunol. 21: 1–12.Google ScholarPubMed
Lando, Z, Teitelbaum, D, Arnon, R (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J. Immunol, 123: 2156–2160.CrossRefGoogle ScholarPubMed
Levine, S, Sowinski, R (1977) Suppression of the hyperacute form of experimental allergic encephalomyelitis by drugs. Arch. Int. Pharmacodyn. 230: 309–318.Google ScholarPubMed
Lhermitte, F, Marteau, R.de Saxce, H (1975) Traitement de la sclerose en plaques par le serum antilymphocytaire. In: Immunopathologie due Systeme Nerveux. Schuller, M.E. (editor): Paris, INSERM. 1341:281–300.Google Scholar
Lukes, SA, Crooks, LE, Aminoff, MJ, Kaufman, L, Panitch, HS, Mills, C, Norman, D (1983) Nuclear magnetic resonance imaging in multiple sclerosis. Ann. Neurol. 13: 592–601.CrossRefGoogle ScholarPubMed
MacFadyen, DJ, Reeve, CE, Bratty, PJA, Thomas, JW (1973) Failure of antilymphocytic globulin therapy in chronic progressive multiple sclerosis. Neurology. 23: 592–598.Google Scholar
McAlpine, D, in McAlpine, D, Lumsden, CE, Acheson, ED (1972) Multiple Sclerosis: A reappraisal. Second Edition, Churchill Livingston, Edinburgh, p. 205.Google Scholar
Mertens, HG, Dommasch, D (1977) Long-term study of immunosuppressive therapy in multiple sclerosis, comparison of periods of the disease before and during treatment. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in Multiple Sclerosis. Ghent, Belgium, European Press, pp. 198–211.Google Scholar
Mertin, J, Kremer, M, Knight, SCet al. (1982) Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: Final report. Lancet. 2: 351–354.CrossRefGoogle ScholarPubMed
Miller, AE (1983) Letter. N. Eng. J. Med. 309: 240.Google Scholar
Millar, JHD, Vas, CJ, Noronha, MJ, Liversedge, LA, Rawson, MD (1967) Long-term treatment of multiple sclerosis with corticotrophin. Lancet 2:429–31.CrossRefGoogle ScholarPubMed
Myers, LW, Ellison, GW, Levy, J, Holevoet, MI, Ma, BI, Tourtellotte, WW (1977). Evaluation of levamisole as a treatment for multiple sclerosis. Neurology 27: 363.Google Scholar
Noseworthy, JH, Paty, DW, Wonnacott, T, Ebers, GC (1983) The markers of prognosis in multiple sclerosis. Ann. Neurol 14: 114.Google Scholar
Noseworthy, JH, Buonanno, FS, Kistler, JP, Rosen, B, New, PFJ, Brady, TJ (1984) True three-dimensional nuclear magnetic resonance neuroimaging in multiple sclerosis. (Submitted, Neurology).Google Scholar
Nussenblatt, RB, Rook, AH, Wacker, WB, Palestine, AG, Scher, I, Gery, I (1983) Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. (8344). 235–238.CrossRefGoogle ScholarPubMed
Oger, J, Deugnier, Y, Hinault, P, Sabouraud, O (1977) Experience of long term immunosuppressive therapy in multiple sclerosis. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive treatment in Multiple Sclerosis. Ghent, Belgium. European Press. pp. 100–113.Google Scholar
Oudin, J, Michel, M (1963) Une nouvelle forme d’allotypie des globulins Ŏ du serum de lapin apparement liée a la fonction et a la spécificité auticorps. C.R. Acad. Sci. 257: 805–808.Google Scholar
Paterson, PY, Hanson, MA (1969) Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J. Immunol. 103: 1311–1316.CrossRefGoogle ScholarPubMed
Paty, DW, Cousin, HK, Read, S, Adlakha, K (1978) Linoleic acid in multiple sclerosis: Failure to show any therapeutic benefit. Acta Neurol. Scandinav. 58: 53–58.CrossRefGoogle ScholarPubMed
Patzgold, U, Haller, P, Haas, J, Pocklington, P, Dreicher, H (1979) Therapie der multiplen sklerose mit levamisole und azathioprine. Nervenarzt. 49: 285–294.Google Scholar
Patzgold, U, Hecker, H, Pocklington, P (1982) Azathioprine in treatment of multiple sclerosis. J. Neurol. Sci. 54: 377–394.CrossRefGoogle Scholar
Penn, I (1982) Malignancies following the use of cyclosporin A in man. Cancer Surveys. 1:621–624.Google Scholar
Penn, I (1982) Malignancies following the use of cyclosporin A in man. Cancer Surveys. 1: 621–624.Google Scholar
Phadke, JG, Best, PV (1983) Atypical and clinically silent multiple sclerosis. A report of 12 cases discovered unexpectedly at necropsy. J. Neurol. Neurosurg. Psychiat. 46: 414–421.CrossRefGoogle ScholarPubMed
Polak, L, Turk, JL (1974) Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature (Lond.). 249: 654.CrossRefGoogle ScholarPubMed
Poser, CM, Paty, DW, Scheinberg, Let al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocals. Ann. Neurol. 13:227–231.CrossRefGoogle Scholar
Ring, J, Lob, G, Angstwurm, H, Brass, B, Backmund, H, Seiffert, J, Coulin, K, Frick, E, Mertin, J, Brandel, W (1974) Intensive immunosuppression in the treatment of multiple sclerosis. Lancet (7889). 1093–1096.CrossRefGoogle ScholarPubMed
Rodkey, LS (1980) Autoregulation of immune responses via idiotype network interactions, Microbiol. Rev. 44: 631–659.Google Scholar
Romine, JS, Salk, J (1983) A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis. In: Hallpike, JF, Adams, CWM, Tourtellotte, WW (Editors): Multiple Sclerosis. Williams and Wilkins, Baltimore, pp. 621–630.Google Scholar
Rose, AS, Kuzma, JW, Kurtzke, JFet al. (1970) Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs placebo. Neurology 20 (Suppl.) 1–59.Google ScholarPubMed
Rosen, J A (1979) Prolonged azathioprine treatment of nonremitting multiple sclerosis. J. Neurol. Neurosurg. Psychiat. 42: 338–344.CrossRefGoogle ScholarPubMed
Schuller, E, Govaerts, A (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur. Neurol. 22:205–212.CrossRefGoogle ScholarPubMed
Schumacher, GA, Beebe, G, Kibler, RFet al. (1965) Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. NY Acad. Sci. 122: 552–568.CrossRefGoogle Scholar
Seland, TP, McPherson, TA, Grace, M, Lamoureux, G, Blain, JG (1974) Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis. Neurology 24: 34–40.CrossRefGoogle ScholarPubMed
Silberberg, D, Lisak, R, Zweiman, B (1973) Multiple sclerosis unaffected by azathioprine in pilot study. Arch. Neurol. 28: 210–212.CrossRefGoogle ScholarPubMed
Steinman, L, Rosenbaum, JT, Sriram, S, McDevitt, HO (1981) In vivo effects of antibodies to immune response gene products; Prevention of experimental allergic encephalitis. Proc. Natl. Acad. Sci. U.S.A. 78:7111–7114.CrossRefGoogle ScholarPubMed
Stiller, CR, Laupacis, A, Dupre, J, Jennar, MR, Keown, PA, Rodger, W, Wolfe, BMJ (1983) Cyclosporin for treatment of early type 1 diabetes: preliminary results. N. Eng. J. Med. 308: 1226–1227.Google ScholarPubMed
Swinburn, WR, Liversedge, LA (1973) Long-term treatment of multiple sclerosis with azathioprine. J. Neurol. Neurosurg. Psychiat. 36:124–126.CrossRefGoogle ScholarPubMed
Teitelbaum, D, Webb, C, Bree, Met al. (1974) Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol. 3: 256–262.CrossRefGoogle ScholarPubMed
Theys, P, Gosseye – Lissoir, F, Ketelaer, P, Carton, H (1981) Short-term intensive cyclophosphamide treatment in Multiple Sclerosis. J. Neurol. 225: 119–133.CrossRefGoogle ScholarPubMed
Tindall, RSA, Walker, JE, Ehle, AL, Near, L, Rollins, J, Becker, D (1982) Plasmaphresis in multiple sclerosis. Prospective trial of pheresis and immunosuppression verses immunosuppression alone. Neurology. 32: 739–743.CrossRefGoogle Scholar
Weiner, HL, Dawson, DM (1980) Plasmapheresis in multiple sclerosis: Preliminary study. Neurology (Minneap.). 30: 1029–33.CrossRefGoogle ScholarPubMed
Whitaker, JN, Lisak, RP, Bashir, RM, Fitch, OH, Seyer, JM, Krance, R, Lawrence, JA, Ch’ien, LT, O’Sullivan, PO (1978) Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann. Neurol. 7: 58–64.CrossRefGoogle Scholar
White, DJG (Editor) Cyclosporin A (1982) New York, Elsevier Press.Google ScholarPubMed
Young, IR, Hall, AS.Pallis, CA, Bydder, GM, Legg, NJ, Steiner, RE (1981) Nuclear Magnetic resonance imaging of the brain in multiple sclerosis. Lancet (8255) 1063–1066.CrossRefGoogle ScholarPubMed